Remarkably different results between two studies from North America on genomic mutations and sensitivity to DNA demethylating agents for myelodysplastic syndromes

摘要：

Sekeres et al.(1) conducted a multicenter randomized,controlled trial to compare whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates to azacitidine in the treatment of myelodysplastic syndromes (MDS).In that trial,224 patients with higher-risk MDS and 53 with chronic myelomonocytic leukemia (CMML) were enrolled and randomly assigned to the ”azacitidine” group,”azacitidine plus lenalidomide” group or ”azacitidine plus vorinostat” group.The researchers found that patients with MDS treated with azacitidine-based combinations had similar response rate to azacitidine monotherapy.

机标关键词：myelodysplastic syndromes、response rate

所属期刊栏目：29

分类号：R73;O4

在线出版日期：2018-02-06（万方平台首次上网日期，不代表论文的发表时间）

页数：共2页

页码：587-588